TD Bank Five Boro Bike Tour
November 8, 2023
HNF is thrilled to have been chosen for the 14th year as a Charity Partner for the TD Bank Five Boro Bike Tour.
News & Stories
The latest from HNF: research updates, patient stories, advocacy wins, events, and CMT community news.
No matches for .
Showing 85 to 96 of 314
-
-
Novartis CMT1A Update
October 23, 2023
In July 2023, Novartis announced the acquisition of DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
-
Congratulations to GRIN Advisory Board member, Professor Joshua Burns
October 19, 2023
Congratulations to GRIN Advisory Board member, Professor Joshua Burns, for being recognized by the Australian Academy of Health and Medical Sciences for his outstanding contributions to medical and health sciences.
-
CMT Meet-Up September 30th at 1pm ET
September 7, 2023
-
Pediatric CMT Natural History Study Enrollment Opening at Two Centers of Excellence
August 31, 2023
Pediatric CMT Natural History Study enhancement to their Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN) patient registry, Global Registry for Inherited Neuropathies (GRIN).
-
CMT Presents: Cohost a CMT Presentation with HNF!
August 29, 2023
HNF is proud to present “CMT Presents,” a virtual presentation series designed to spread awareness in the communities, companies, and groups closest to you!
-
DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
August 2, 2023
Dtx today announced that the FDA has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
-
Great News From HNF TRIAD Industry Partner, Pharnext
August 2, 2023
Pharnext announces new positive results from the ongoing open-label extension study of their drug PXT3003
-
Great News From HNF TRIAD Industry Partner, Applied Therapeutics
August 2, 2023
Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation
-
Using Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease, Patient Reported Outcomes
August 2, 2023
Data regarding medical cannabis use for pain relief in CMT from HNF’s CMT Patient Registry, GRIN
-
9 Key Findings from Your GRIN Surveys (and why you need to come back and complete more)
July 13, 2023
The study highlights the significant impact of neuropathic pain on the quality of life and psychosocial well-being of individuals with CMT.
